T
Tim
Washington University School of Medicine
Research areas: Biochemistry, Genetics and Molecular Biology · Molecular Biology · PI3K/AKT/mTOR signaling in cancer · Breast Cancer Treatment Studies · PARP inhibition in cancer therapy
0000-0002-3240-8989
Employment
Employment history is unavailable.
Education
-
Washington University School of Medicine
Projects & Funding
Projects & funding information is unavailable.
Publications (23)
- Unraveling TIME: CD8+ T cell– and CXCL11-driven endocrine resistance in breast cancer Save
- Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial Save
- Patient-specific enhancers in genetically uniform leukemias Save
- RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia Save
- RSK1 dependency in FLT3-ITD acute myeloid leukemia Save
- In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms Save
- Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer Save
- A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis. Save
- Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms. Save
- Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms Save
- Complementary and countervailing actions of Jak2 and Ikk2 in hematopoiesis in mice Save
- Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis Save
- Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms Save
- DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression Save
- Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib Save
- Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition Save
- CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers Save
- eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer Save
- CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary Save
- SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer Save